Clene Inc., a biopharmaceutical company incorporated in Delaware, has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an equity offering. The filing, dated October 1, 2024, reports that the company has successfully raised $7,310,060 USD through the sale of securities. The offering, which did not last more than one year, included equity, options, warrants, and other rights to acquire additional securities. Clene Inc. has declined to disclose the issuer size in terms of revenue or aggregate net asset value. The company has also claimed an exemption under Rule 506(b) of the Securities Act. The filing lists several executive officers and directors, including President and CEO Robert Etherington, who signed the submission on October 9, 2024. No sales commissions or finders' fees were reported, and the proceeds from the offering are not intended for payments to the named executive officers, directors, or promoters.

Clene Inc., a biopharmaceutical company incorporated in Delaware, has filed a Form D Notice of Exempt Offering of Securities with the SEC, indicating a new notice for an equity offering. The filing, dated October 1, 2024, reports that the company has successfully raised $7,310,060 USD through the sale of securities. The offering, which did not last more than one year, included equity, options, warrants, and other rights to acquire additional securities. Clene Inc. has declined to disclose the issuer size in terms of revenue or aggregate net asset value. The company has also claimed an exemption under Rule 506(b) of the Securities Act. The filing lists several executive officers and directors, including President and CEO Robert Etherington, who signed the submission on October 9, 2024. No sales commissions or finders' fees were reported, and the proceeds from the offering are not intended for payments to the named executive officers, directors, or promoters.